Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid
- 10 October 2007
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 214 (1), 201-209
- https://doi.org/10.1002/jcp.21188
Abstract
Fish oil rich in n−3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) protects inflammation induced bone loss in chronic inflammatory diseases like rheumatoid arthritis, periodontitis, and osteoporosis. EPA and DHA differentially regulate functional parameters and gene expression in different cell types. One of the risk factors for bone loss in inflammatory bone diseases is the elevation of bone‐resorbing osteoclasts and a very few studies so far have indicated that attenuation of osteoclastogenesis might be one of the mechanisms by which n−3 PUFA exert its effect on bone loss protection. However, the precise mechanism underlying this process remains unclear. Receptor activator of NF‐κB ligand (RANKL) is known to be the most critical mediator of osteoclastogenesis. Therefore, in this study, we examined the differential effect of EPA and DHA on RANKL‐stimulated osteoclastogenesis and RANKL signaling using a murine monocytic cell line RAW 264.7. DHA was found to inhibit osteoclast differentiation, activation and function more potently than EPA. The differential potential also closely correlated with the inhibition of osteoclast‐specific genes like tartrate resistant acid phosphatase, cathepsin K, calcitonin receptor, matrix metalloproteinase‐9 expression and osteoclast‐specific transcription factor, c‐Fos, as well as osteotropic proinflammatory cytokine, TNF‐α to a greater extent with DHA than EPA. Further, pretreatment of RAW 264.7 cells with DHA also showed significantly reduced activation of NF‐κB and p38MAPK than EPA. Our findings suggest that DHA may be much more effective than EPA in alleviating RANKL induced proinflammatory cytokine production, intracellular signaling activation, thereby decreasing osteoclast activation and bone resorption. J. Cell. Physiol. 214:201–209, 2008.This publication has 57 references indexed in Scilit:
- Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acidThe Journal of Nutritional Biochemistry, 2007
- Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitisProceedings of the National Academy of Sciences of the United States of America, 2006
- Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factorBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2006
- Anti-inflammatory action of dietary fish oil and calorie restrictionLife Sciences, 2006
- Comparative effects of eicosapentaenoic acid and docosahexaenoic acid on proliferation, cytokine production, and pleiotropic gene expression in Jurkat cellsThe Journal of Nutritional Biochemistry, 2004
- Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophagesBlood, 2003
- The combination of tumor necrosis factor ? blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo modelArthritis & Rheumatism, 2001
- IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJCI Insight, 1999
- Dietary Effect of EPA-rich and DHA-rich Fish Oils on the Immune Function of Sprague-Dawley RatsBioscience, Biotechnology, and Biochemistry, 1999
- Long‐term effect of omega‐3 fatty acid supplementation in active rheumatoid arthritisArthritis & Rheumatism, 1994